A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.
Rongrui Liu, Xianli Yin, Yuxian Bai, Haijun Zhong, Feng Ye, Qi Wang, Mulin Liu, Ning Li, Yanhong Deng, Yusheng Wang, Jinxiu Xu, Wei Li, Kehe Chen, Sanjun Cai, Jianwei Yang, Tao Zhang, Yunfeng Li, Baoli Qin, Lichun Deng, Shulin Liu, Sicong Li, Jing Si, Yaling Li, Junyou Ge, Nong Xu, Jianming Xu
Eur J Cancer 226 115566
摘要
摘要
PURPOSE: EGFR inhibition, combined with chemotherapy, forms a mainstay of treatment of first-line RAS wild-type (RASwt) metastatic CRC (mCRC). We compared the anti-EGFR antibody, A140, with cetuximab (both combined with chemotherapy) for RASwt mCRC. METHODS: In this phase 3, randomized, double-blind, multi-center equivalence trial in China, patients were randomized (1:1) to oxaliplatin, 5-fluorouracil, and leucovorin (modified [m] FOLFOX6), plus either A140 or cetuximab for ≤ 16 weeks until disease progression or unacceptable toxicity. After the 16-week treatment period, patients who investigators deemed could benefit received A140 plus mFOLFOX6. Eligible patients were 18-75 years old with histologically confirmed RASwt mCRC and an Eastern Cooperative Oncology Group (ECOG) score of 0-1. Primary endpoint was objective response rate (ORR [RECIST v1.1]), per independent review committee, over the 16 weeks. A140 was considered equivalent if the 90 % CIs for the ORR ratio were between 0.83 and 1.20. Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, immunogenicity, and pharmacokinetics. RESULTS: Overall, 688 patients were randomized to A140 (n = 341) or cetuximab (n = 347). As of 22-Mar-2023, the ORR was 71.0 % (A140) and 77.5 % (cetuximab); the ORR ratio was 0.93 (90 % CI, 0.87-0.99). With a median follow-up of 19.6 months, no notable differences in PFS, OS, or duration of response were observed between arms. Safety profiles and immunogenicity were similar between arms and no new safety signals were observed. CONCLUSION: A140 plus mFOLFOX6 is equivalent to cetuximab plus mFOLFOX6 for RASwt mCRC, with no appreciable differences in safety profiles. A140 plus mFOLFOX6 may provide a new treatment option for patients with RASwt mCRC. TRIAL REGISTRATION: NCT04835142.
KM 提取结果
0 个 Figure · 0 个 KM 面板